Figure 9.
Schematic illustration of the mechanisms underlying the immunopotentiating effect of the proteoglycan TPG-1 from Huaier. TPG-1 exerted anti-tumor activity partially through the immunopotentiating effect that resulted from up-regulation of TNFα, IL-6, and NO, mediated by TLR4-dependent activation of NF-κB and MAPK signaling pathways.